Common progenitor cells in mature B-cell malignancies

Implications for therapy

Michael R Green, Ash A. Alizadeh

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This review summarizes the recent progress in defining the patterns of genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses their implications with respect to 'personalized medicine'. RECENT FINDINGS: High-throughput sequencing studies have uncovered a large degree of clonal heterogeneity within tumors, and found that subclones have a variable contribution to relapse. Recent studies aimed at defining patterns of clonal evolution have revealed that serial tumors in some malignancies share their ancestry in a less evolved common progenitor cell (CPC) that bears only a subset of the mutations that are present in the fully evolved tumors that present clinically. This pattern of 'divergent evolution' means that the majority of 'actionable mutations' in tumor specimens are absent within the progenitors that give rise to relapse. SUMMARY: Follicular lymphoma and multiple myeloma are clinically, biologically and genetically distinct mature B-cell malignancies. However, recent studies have found them to share important similarities in their patterns of genetic evolution. Tumor cells that constitute subclonal populations within these tumors, or between consecutive tumors, share their origins within a genetically less evolved common progenitor cell. This pattern of evolution indicates that current therapies are unable to eradicate these less evolved populations that are at the root of relapse. This suggests that in order to obtain the best results with modern 'targeted therapies' that are directed towards 'actionable mutations', these mutations should be considered within the context of the evolutionary stage at which mutations are acquired, not simply on a presence or absence basis.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalCurrent Opinion in Hematology
Volume21
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

B-Lymphocytes
Stem Cells
Neoplasms
Mutation
Recurrence
Follicular Lymphoma
Therapeutics
Molecular Evolution
Multiple Myeloma
Clonal Evolution
Precision Medicine
Population

Keywords

  • Clonal evolution
  • Common progenitor cell
  • Follicular lymphoma
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Common progenitor cells in mature B-cell malignancies : Implications for therapy. / Green, Michael R; Alizadeh, Ash A.

In: Current Opinion in Hematology, Vol. 21, No. 4, 01.01.2014, p. 333-340.

Research output: Contribution to journalReview article

Green, Michael R ; Alizadeh, Ash A. / Common progenitor cells in mature B-cell malignancies : Implications for therapy. In: Current Opinion in Hematology. 2014 ; Vol. 21, No. 4. pp. 333-340.
@article{48b56c6cace449798e990bf4181ca00b,
title = "Common progenitor cells in mature B-cell malignancies: Implications for therapy",
abstract = "PURPOSE OF REVIEW: This review summarizes the recent progress in defining the patterns of genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses their implications with respect to 'personalized medicine'. RECENT FINDINGS: High-throughput sequencing studies have uncovered a large degree of clonal heterogeneity within tumors, and found that subclones have a variable contribution to relapse. Recent studies aimed at defining patterns of clonal evolution have revealed that serial tumors in some malignancies share their ancestry in a less evolved common progenitor cell (CPC) that bears only a subset of the mutations that are present in the fully evolved tumors that present clinically. This pattern of 'divergent evolution' means that the majority of 'actionable mutations' in tumor specimens are absent within the progenitors that give rise to relapse. SUMMARY: Follicular lymphoma and multiple myeloma are clinically, biologically and genetically distinct mature B-cell malignancies. However, recent studies have found them to share important similarities in their patterns of genetic evolution. Tumor cells that constitute subclonal populations within these tumors, or between consecutive tumors, share their origins within a genetically less evolved common progenitor cell. This pattern of evolution indicates that current therapies are unable to eradicate these less evolved populations that are at the root of relapse. This suggests that in order to obtain the best results with modern 'targeted therapies' that are directed towards 'actionable mutations', these mutations should be considered within the context of the evolutionary stage at which mutations are acquired, not simply on a presence or absence basis.",
keywords = "Clonal evolution, Common progenitor cell, Follicular lymphoma, Multiple myeloma",
author = "Green, {Michael R} and Alizadeh, {Ash A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MOH.0000000000000049",
language = "English (US)",
volume = "21",
pages = "333--340",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Common progenitor cells in mature B-cell malignancies

T2 - Implications for therapy

AU - Green, Michael R

AU - Alizadeh, Ash A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE OF REVIEW: This review summarizes the recent progress in defining the patterns of genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses their implications with respect to 'personalized medicine'. RECENT FINDINGS: High-throughput sequencing studies have uncovered a large degree of clonal heterogeneity within tumors, and found that subclones have a variable contribution to relapse. Recent studies aimed at defining patterns of clonal evolution have revealed that serial tumors in some malignancies share their ancestry in a less evolved common progenitor cell (CPC) that bears only a subset of the mutations that are present in the fully evolved tumors that present clinically. This pattern of 'divergent evolution' means that the majority of 'actionable mutations' in tumor specimens are absent within the progenitors that give rise to relapse. SUMMARY: Follicular lymphoma and multiple myeloma are clinically, biologically and genetically distinct mature B-cell malignancies. However, recent studies have found them to share important similarities in their patterns of genetic evolution. Tumor cells that constitute subclonal populations within these tumors, or between consecutive tumors, share their origins within a genetically less evolved common progenitor cell. This pattern of evolution indicates that current therapies are unable to eradicate these less evolved populations that are at the root of relapse. This suggests that in order to obtain the best results with modern 'targeted therapies' that are directed towards 'actionable mutations', these mutations should be considered within the context of the evolutionary stage at which mutations are acquired, not simply on a presence or absence basis.

AB - PURPOSE OF REVIEW: This review summarizes the recent progress in defining the patterns of genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses their implications with respect to 'personalized medicine'. RECENT FINDINGS: High-throughput sequencing studies have uncovered a large degree of clonal heterogeneity within tumors, and found that subclones have a variable contribution to relapse. Recent studies aimed at defining patterns of clonal evolution have revealed that serial tumors in some malignancies share their ancestry in a less evolved common progenitor cell (CPC) that bears only a subset of the mutations that are present in the fully evolved tumors that present clinically. This pattern of 'divergent evolution' means that the majority of 'actionable mutations' in tumor specimens are absent within the progenitors that give rise to relapse. SUMMARY: Follicular lymphoma and multiple myeloma are clinically, biologically and genetically distinct mature B-cell malignancies. However, recent studies have found them to share important similarities in their patterns of genetic evolution. Tumor cells that constitute subclonal populations within these tumors, or between consecutive tumors, share their origins within a genetically less evolved common progenitor cell. This pattern of evolution indicates that current therapies are unable to eradicate these less evolved populations that are at the root of relapse. This suggests that in order to obtain the best results with modern 'targeted therapies' that are directed towards 'actionable mutations', these mutations should be considered within the context of the evolutionary stage at which mutations are acquired, not simply on a presence or absence basis.

KW - Clonal evolution

KW - Common progenitor cell

KW - Follicular lymphoma

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84902275099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902275099&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000049

DO - 10.1097/MOH.0000000000000049

M3 - Review article

VL - 21

SP - 333

EP - 340

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -